Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention

Cancer Letters

Volumn 134, Issue 2, 1998, Pages 201-207

  Winde, Guenther ^a   Lügering, Norbert ^a   Glodny, Bernhard ^a   Schmid, Kurt W ^b   Müller, Oliver ^c   Senninger, Norbert ^a   Osswald, Hans ^d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chemoprevention; FAP; HER 2 c erbB 2 neu; NSAID sulindac; Tyrosine kinase

Indexed keywords

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SULINDAC; TYROSINE KINASE RECEPTOR;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL POLYPOSIS; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTAL DRUG ADMINISTRATION; RECTUM CANCER; RECTUM MUCOSA;

ADENOMATOUS POLYPOSIS COLI; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; DOWN-REGULATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECTUM; SULINDAC;

EID: 0344097440     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00254-7     Document Type: Article

References (41)

1. Akiyama T., Sudo G., Ogawara H., Totoshima K., Yamamoto T. The product of the human c-erbB-2 gene: a 185 kilodalton glycoprotein with tyrosine kinase activity. Science. 232:1986;1644-1646.
2. Allred D.C., Clark G.M., Tandon A.K., Molina R., Tormey D.C., Osborne C.K., Gilchrist K.W., Mansour E.G., Abeloff M., Eudey L., McGuire W.L. HER-2/HER-2 in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol. 10:1992;599-605.
3. Arnaout A.H., Dawson P.M., Soomro S., et al. HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. J. Clin. Pathol. 45:1992;726-727.
4. Bargmann C.I., Hung M.-C., Weinberg R.A. Multiple independent activations of the HER-2 oncogene by a point mutation altering the transmembrane domain of p185. Cell. 45:1986;649-657.
5. Berger M.S., Locher G.W., Saurer S., Gullick W.J., Waterfield M.D., Groner B., Hynes N.E. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinomas with nodal status and nuclear grading. Cancer Res. 48:1988;1238-1243.
6. Bollbol S.K., Dannenberg A.J., Chadburn A., Martucci C., Guo X.J., Ramonetti J.T., Abreu-Goris M., Newmark H.L., Lipkin M.L., DeCosse J.J., Bertagnolli M.M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56:1996;2556-2560.
7. Borg A., Baldetorp B., Fernö M., Killander D., Olsson H., Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene. 6:1991;137-143.
8. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-252.
9. Carney W.P., Hamer P.J., Petit D., Retos C., Greene R., Zabrecky J.R., McKenzie S., Hayes S., Kufe D., DeLellis R., Naber R., Wolfe H. Detection and quantification of the human HER-2 oncoprotein. Tumor Marker Oncol. 6:1991;53-72.
10. D'Emilia J., Bulovas K., D'Ercole K., Wolf B., Steele G. Jr., Summerhayes I.C. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene. 4:1989;1233-1239.
11. Elder D.J.E., Halton D.E., Hague A., Paraskeva C. Induction of apoptotic cell death in human colorectal cancer cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 3:1997;1679-1683.
12. Elledge R.M., Green S., Ciocca D., Pugh R., Allred D.C., Clark G.M., Hill J., Ravdin P., O'Sullivan J., Martino S., Osborne C.K. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin. Cancer Res. 4:1998;7-12.
13. Galandiuk S., Miseljic S., Yang A.-R., Early M., McCoy M.D., Wittliff J.L. Expression of hormone receptors, cathepsin D and HER-2/neu oncoprotein in normal colon and colonic disease. Arch. Surg. 128:1993;637-642.
14. Giardiello F.M., Offerhaus J.A., Tersmette A.C., Hylind L.M., Krush A.J., Brensinger J.D., Booker S.V., Hamilton S.R. Sulindac induces regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut. 38:1996;578-581.
15. Grunt T.W., Huber H. The family of c-erbB genes: from basic research to clinical oncology. Onkologie. 17:1994;346-357.
16. P. Hermanek, L.H. Sobin (Eds.), TNM Classification of Malignant Tumours, Springer, Berlin, 1987, pp. 49-52.
17. J.R. Jass, L.H. Sobin (Eds.), Histological Typing of Intestinal Tumours, Springer, Berlin, 1987, pp. 29-32.
18. Kath R., Höffken K., Otte C., Metz K., Scheulen M.E., Hülskamp F., Seeber S. The HER-2-oncogene product in serum and tissue of patients with breast carcinoma. Ann. Oncol. 4:1993;585-590.
19. Kluftinger A.M., Robinson B.W., Quenville N.F., Finley R.J., Davis N.L. Correlation of epidermal growth factor receptor and c-erbB-2 oncogene product to known prognostic indicators of colorectal cancer. Surg. Oncol. 1:1992;97-105.
20. Lacroix H., Iglehart J.D., Skinner M.A., Kraus M.H. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinomas is detected simultaneously in matched primary tumors and regional metastases. Oncogene. 4:1989;145-151.
21. LaRocca R.V., Park J.-G., Danesi R., Del Tacca M., Steinberg S.M., Gazdar A.F. Pattern of growth factor, proto-oncogene and carcinoembryonic antigen gene expression in human colorectal carcinoma cell lines. Oncology. 49:1992;209-214.
22. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 267:1995;1782-1788.
23. H. Motulsky (Ed.), Intuitive Biostatistics, Oxford University Press, New York, 1995.
24. Munemitsu S., Albert I., Souza B., Rubinfeld B., Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor suppressor protein. Proc. Natl. Acad. Sci. USA. 92:1995;3046-3050.
25. Nugent K.P., Farmer K.C., Spigelman A.D., Williams C.B., Phillips R.K.S. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 80:1993;1618-1619.
26. Padhy L.C., Shih C., Cowing D., Finkelstein R., Weinberg R.A. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell. 28:1982;865-871.
27. Pasricha P.J., Bedi A., O'Connor K., Rashid A., Akhtar A.J., Zahurak M.L., Piantadosi S., Hamilton S.R. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology. 109:1995;994-998.
28. Piazza G.A., Kulchak Rahm A.L., Krutzsch M., Sperl G., Paranka N.S., Gross P.H., Brendel K., Burt R.W., Alberts D.S., Pamukcu R., Ahnen D.J. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55:1995;3110-3116.
29. Sainsbury J.R.C., Farndon J.R., Needham G.K., Malcolm A.J., Harris A.L. Epidermal growth factor receptor status as predictor of early recurrence and of death from breast cancer. Lancet. i:1987;1398-1402.
30. Sato M., Narita T., Kawakami-Kimura N., Higashiyama S., Taniguchi N., Akiyama S., Hashimoto T., Manabe T., Kannagi R. Increased expression of integrins by heparin-binding EGF like growth factor in human esophageal cancer cells. Cancer Lett. 102:1996;183-191.
31. Shen T.Y., Witzel B.E., Jones H., Linn B.O., McPherson J., Greenwald R., Fordice M., Jacobs A. Synthesis of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)-bezylidenyl]-indene-3-acetic acid. Fed. Proc. 31:1972;577.
32. Singh J., Rao C.V., Kulkarni N., Simi B., Reddy B.S. Molecular markers as intermediate end-points in chemoprevention of colon cancer: modulation of ras activation by sulindac and phenylhexylisothiocanate during colon carcinogenesis. Int. J. Oncol. 5:1994;1009-1018.
33. Smalley W.E., DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 39:1997;1-20.
34. Vogel W., Kath R., Kosmehl H., Olschowsky E., Höffken K. The HER-2 oncogene product in serum and tissue of patents with metastatic gastrointestinal carcinomas. J. Cancer Res. Clin. Oncol. 122:1996;118-121.
35. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alteration during colorectal tumor-development. N. Engl. J. Med. 319:1988;525-532.
36. Weiner D.B., Liu J., Cohen J.A., Williams W.V., Greene M.I. A point mutation in the HER-2 oncogene mimics ligand induction of receptor aggregation. Nature. 339:1989;230-231.
37. Winde G., Schmid K.W., Brandt B., Müller O., Osswald H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis. Colon Rectum. 40:1997;1156-1169.
38. Winde G., Schmid K.W., Schlegel W., Fischer R., Osswald H., Bünte H. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment: advantages of a low-dose non-steroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis. Colon Rectum. 38:1995;813-830.
39. Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., Saito T., Toyoshima K. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature. 319:1986;230-234.
40. Yang J.L., Yu Y., Markovic B., Russel P.J., Crowe P.J. Overexpression of c-erbB-2 mRNA and/or c-neu oncoprotein is a predictor for metastases from colorectal cancer. Anticancer Res. 17:1997;1023-1026.
41. Yonemura Y., Ninomiya I., Yamaguchi A., Fushida S., Kimura H., Ohoyama S., Miyazaki I., Endou Y., Tanaka M., Sasaki T. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 51:1991;1034-1038.